 |
77 Diseases |  |
69 Trials |
|
69 Trials |  |
4434 News |  |
| «12...34353637383940414243444546» |
- efavirenz / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment closed: LIPOKAL: Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients (clinicaltrials.gov) - Feb 20, 2013
P4, N=20, Active, not recruiting, Sponsor: Juan A. Arnaiz
Recruiting --> Active, not recruiting
- Trial completion: ADVANZ-3: Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl (clinicaltrials.gov) - Feb 20, 2013
P4, N=108, Completed, Sponsor: Juan A. Arnaiz
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment change: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - Feb 11, 2013
P4, N=1300, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed N=800 --> 1300
- | Trial completion: Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth (clinicaltrials.gov) - Jan 23, 2013
P3, N=451, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=800 --> 1300 Active, not recruiting --> Completed
- lopinavir/ritonavir / Generic mfg.
Enrollment closed: Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women (clinicaltrials.gov) - Jan 22, 2013
P2, N=23, Active, not recruiting, Sponsor: AIDS Clinical Trials Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Selzentry (maraviroc) / ViiV Healthcare
Trial completion: Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects (clinicaltrials.gov) - Jan 22, 2013
P4, N=30, Completed, Sponsor: Germans Trias i Pujol Hospital
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | nevirapine / Generic mfg., lopinavir/ritonavir / Generic mfg.
New P4 trial, IO biomarker: Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting (clinicaltrials.gov) - Jan 17, 2013
P4, N=425, Completed, Sponsor: Centre Hospitalier Universitaire Saint Pierre
- efavirenz / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial termination, Metastases: Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease (clinicaltrials.gov) - Jan 15, 2013
P4, N=15, Terminated, Sponsor: Rush University Medical Center
Recruiting --> Terminated; Study stopped 12/2010 due to poor enrollment. Only 15 of 60 needed enrolled.
- efavirenz / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment change, Metastases: Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease (clinicaltrials.gov) - Jan 15, 2013
P4, N=15, Terminated, Sponsor: Rush University Medical Center
Only 15 of 60 needed enrolled. N=60 --> 15
- ||| lopinavir/ritonavir / Generic mfg.
Enrollment change, Biopsy: Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score (clinicaltrials.gov) - Jan 1, 2013
P4, N=86, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=60 --> 15 N=133 --> 86
- |||| lopinavir/ritonavir / Generic mfg.
Trial completion, Biopsy: Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score (clinicaltrials.gov) - Jan 1, 2013
P4, N=86, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=133 --> 86 Terminated --> Completed
- zidovudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
New P2 trial, Combination therapy: A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects (clinicaltrials.gov) - Nov 28, 2012
P2, N=0, Withdrawn, Sponsor: RFS Pharma, LLC
- lopinavir/ritonavir / Generic mfg.
Trial completion: Comparison of Liquid Kaletra and Low Dose Kaletra Tablets (clinicaltrials.gov) - Nov 28, 2012
P=N/A, N=8, Completed, Sponsor: Phoenix Children's Hospital
Terminated --> Completed Active, not recruiting --> Completed
- | efavirenz / Generic mfg., abacavir / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment closed: NEVEREST-III: Treatment Options for Protease Inhibitor-exposed Children (clinicaltrials.gov) - Nov 17, 2012
P3, N=400, Active, not recruiting, Sponsor: Columbia University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial termination: Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV (clinicaltrials.gov) - Nov 15, 2012
P2, N=130, Terminated, Sponsor: AIDS Clinical Trials Group
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; The DSMB concluded that the findings regarding the primary analysis would persist and that no additional study goals would be achieved by continuing the study.
- | Prezista (darunavir) / J&J, Viracept (nelfinavir) / ViiV Healthcare, Roche
Enrollment change: Clinical Trial of CNS-targeted HAART (CIT2) (clinicaltrials.gov) - Nov 8, 2012
P2/3, N=59, Completed, Sponsor: University of California, San Diego
Active, not recruiting --> Terminated; The DSMB concluded that the findings regarding the primary analysis would persist and that no additional study goals would be achieved by continuing the study. N=120 --> 59
- | Prezista (darunavir) / J&J, Viracept (nelfinavir) / ViiV Healthcare, Roche
Trial completion: Clinical Trial of CNS-targeted HAART (CIT2) (clinicaltrials.gov) - Nov 8, 2012
P2/3, N=59, Completed, Sponsor: University of California, San Diego
N=120 --> 59 Recruiting --> Completed
- Trial withdrawal: ALISA: A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir (clinicaltrials.gov) - Nov 6, 2012
P3, N=0, Withdrawn, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: ALISA: A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir (clinicaltrials.gov) - Nov 6, 2012
P3, N=0, Withdrawn, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Not yet recruiting --> Withdrawn N=386 --> 0
- ||| Cresemba (isavuconazonium sulfate) / Astellas, Basilea, Pfizer, Laboratoire Riva, Asahi Kasei
Trial completion: Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole (clinicaltrials.gov) - Nov 6, 2012
P1, N=68, Completed, Sponsor: Astellas Pharma Global Development, Inc.
N=386 --> 0 Recruiting --> Completed
- Enrollment change: Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth (clinicaltrials.gov) - Nov 4, 2012
P2, N=175, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed N=300 --> 175
- Trial completion: Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth (clinicaltrials.gov) - Nov 4, 2012
P2, N=175, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=300 --> 175 Active, not recruiting --> Completed
- lopinavir/ritonavir / Generic mfg.
Enrollment change: Differences in Blood Levels of Lopinavir/Ritonavir in HIV Infected Men and Women (clinicaltrials.gov) - Oct 25, 2012
P=N/A, N=116, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed N=78 --> 116
- Trial completion: Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients (clinicaltrials.gov) - Oct 24, 2012
P=N/A, N=150, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=78 --> 116 Active, not recruiting --> Completed
- tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment change: Kaletra and Viread in Antiretroviral Na (clinicaltrials.gov) - Oct 8, 2012
P4, N=6, Terminated, Sponsor: Oklahoma State University Center for Health Sciences
Active, not recruiting --> Completed N=30 --> 6
- rifampicin / Generic mfg., lopinavir/ritonavir / Generic mfg.
New P4 trial, Combination therapy: Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin (clinicaltrials.gov) - Oct 2, 2012
P4, N=12, Not yet recruiting, Sponsor: University of Miami
- Enrollment change: Sex, Aging and Antiretroviral Pharmacokinetics (clinicaltrials.gov) - Sep 17, 2012
P=N/A, N=11, Completed, Sponsor: Kristine Patterson, MD
N=30 --> 6 N=42 --> 11
- Trial completion: Sex, Aging and Antiretroviral Pharmacokinetics (clinicaltrials.gov) - Sep 17, 2012
P=N/A, N=11, Completed, Sponsor: Kristine Patterson, MD
N=42 --> 11 Recruiting --> Completed
- lopinavir/ritonavir / Generic mfg.
Enrollment open, Monotherapy: Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily (clinicaltrials.gov) - Sep 3, 2012
P4, N=30, Recruiting, Sponsor: Daniel Podzamczer
Recruiting --> Completed Not yet recruiting --> Recruiting
- lopinavir/ritonavir / Generic mfg.
New P1 trial: ALternative TEnofovir Dosing in Adults With Moderate Renal Function Impairment (clinicaltrials.gov) - Aug 22, 2012
P1, N=40, Active, not recruiting, Sponsor: Institut de Recherche pour le Developpement
- ||||| Mycobutin (rifabutin) / Pfizer, Lupin
New P2 trial: EARNEST Rifabutin Pharmacokinetics (PK) Substudy (clinicaltrials.gov) - Aug 9, 2012
P2, N=140, Recruiting, Sponsor: Justine Boles
- ||| lopinavir/ritonavir / Generic mfg.
Adherence: Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program (clinicaltrials.gov) - Aug 8, 2012
P=N/A, N=240, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
- ||| Cresemba (isavuconazonium sulfate) / Astellas, Basilea, Pfizer, Laboratoire Riva, Asahi Kasei
New P1 trial: Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole (clinicaltrials.gov) - Aug 6, 2012
P1, N=68, Completed, Sponsor: Astellas Pharma Global Development, Inc.
- | lopinavir/ritonavir / Generic mfg.
Enrollment closed: Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL) (clinicaltrials.gov) - Jul 23, 2012
P3, N=240, Active, not recruiting, Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- Coarsucam (artesunate/amodiaquine) / Sanofi, DNDi
Trial completion: Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations (clinicaltrials.gov) - Jul 11, 2012
P1, N=38, Completed, Sponsor: Fran Aweeka
Not yet recruiting --> Active, not recruiting Recruiting --> Completed
- efavirenz / Generic mfg., artemether/lumefantrine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion: Drug Interaction Study Between Antimalarial and Anti-HIV Medications (clinicaltrials.gov) - Jul 11, 2012
P1, N=33, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed Recruiting --> Completed
- | nevirapine / Generic mfg., lopinavir/ritonavir / Generic mfg.
New P4 trial: DATiC: Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study) (clinicaltrials.gov) - Jul 9, 2012
P4, N=240, Recruiting, Sponsor: University of Cape Town
- | New P1/2 trial: Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected (clinicaltrials.gov) - Jul 1, 2012
P1/2, N=52, Recruiting, Sponsor: AIDS Clinical Trials Group
- lopinavir/ritonavir / Generic mfg.
Trial initiation date: TiP: Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV (clinicaltrials.gov) - Jun 25, 2012
P2, N=80, Recruiting, Sponsor: Centers for Disease Control and Prevention
Recruiting --> Completed Initiation date: Jan 2012 --> May 2012
- lopinavir/ritonavir / Generic mfg.
Enrollment open: TiP: Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV (clinicaltrials.gov) - Jun 25, 2012
P2, N=80, Recruiting, Sponsor: Centers for Disease Control and Prevention
Initiation date: Jan 2012 --> May 2012 Not yet recruiting --> Recruiting
- Isentress (raltegravir) / Merck (MSD)
Enrollment change: PLUS: Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut (clinicaltrials.gov) - Jun 17, 2012
P=N/A, N=8, Completed, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting N=12 --> 8
- Isentress (raltegravir) / Merck (MSD)
Trial completion: PLUS: Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut (clinicaltrials.gov) - Jun 17, 2012
P=N/A, N=8, Completed, Sponsor: University of California, San Francisco
N=12 --> 8 Recruiting --> Completed
- ||||||| lamivudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion: GARDEL: Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Na (clinicaltrials.gov) - Jun 7, 2012
P3, N=417, Completed, Sponsor: Pedro Cahn
Recruiting --> Completed Recruiting --> Completed
- | Isentress (raltegravir) / Merck (MSD)
Trial initiation date, Combination therapy: Study of Options for Second-Line Effective Combination Therapy (SELECT) (clinicaltrials.gov) - May 30, 2012
P3, N=600, Active, not recruiting, Sponsor: AIDS Clinical Trials Group
Recruiting --> Completed Initiation date: Oct 2011 --> Jan 2012
- || lopinavir/ritonavir / Generic mfg.
Trial completion, Monotherapy: Kaletra Monotherapy in HIV/HCV Co-infected Subjects (clinicaltrials.gov) - May 27, 2012
P3, N=22, Completed, Sponsor: Ottawa Hospital Research Institute
Initiation date: Oct 2011 --> Jan 2012 Active, not recruiting --> Completed
- | Mycobutin (rifabutin) / Pfizer, Lupin, Isentress (raltegravir) / Merck (MSD)
New P2 trial: Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV (clinicaltrials.gov) - May 16, 2012
P2, N=471, Recruiting, Sponsor: AIDS Clinical Trials Group
- nevirapine / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment change: Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Populations Using Formula Feeding (PROMISE) (clinicaltrials.gov) - Apr 26, 2012
P=N/A, N=1000, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed N=2000 --> 1000
- lopinavir/ritonavir / Generic mfg.
Enrollment change: Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women (clinicaltrials.gov) - Apr 19, 2012
P2, N=32, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=2000 --> 1000 N=54 --> 32
- Invirase (saquinavir) / Roche
Enrollment change, IO biomarker: A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy (clinicaltrials.gov) - Apr 19, 2012
P2, N=6, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=54 --> 32 N=254 --> 6
- abacavir / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment change, IO biomarker: Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV (clinicaltrials.gov) - Apr 19, 2012
P3, N=19, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=254 --> 6 N=880 --> 19